PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung

1Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-35. 10.1056/NEJMoa1504627BrahmerJReckampKLBaasPCrinoLEberhardtWEPoddubskayaE Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 2015 373 12335 10.1056/NEJMoa1504627Open DOISearch in Google Scholar

2Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-39. 10.1056/NEJMoa1507643BorghaeiH Paz-AresLHornLSpigelDRSteinsMReadyNE Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 2015 373 1627 39 10.1056/NEJMoa1507643Open DOISearch in Google Scholar

3Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-50. 10.1016/S0140-6736(15)01281-7HerbstRSBaasPKimDWFelipE Perez-GraciaJLHanJY Pembrolizumab versus docetaxel for previously treated PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Lancet 2016 387 1540 50 10.1016/S0140-6736(15)01281-7Open DOISearch in Google Scholar

4Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016; 387: 1837-46. 10.1016/S0140-6736(16)00587-0FehrenbacherLSpiraABallingerMKowanetzMVansteenkisteJMazieresJ Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre open-label, phase 2 randomised controlled trial Lancet 2016 387 1837 46 10.1016/S0140-6736(16)00587-0Open DOISearch in Google Scholar

5Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017; 389: 255-65. 10.1016/S0140-6736(16)32517-XRittmeyerABarlesiFWaterkampDParkKCiardielloF von PawelJ Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Lancet 2017 389 255 65 10.1016/S0140-6736(16)32517-XOpen DOISearch in Google Scholar

6Besse B, Johnson M, Janne PA, Garassino M, Eberhardt WEE, Peters S, et al. Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). [abstract]. Eur J Cancer 2015; 51(Suppl 3),: abstr 16LBA, S717-18. 10.1016/S0959-8049(16)31938-4BesseBJohnsonMJannePAGarassinoMEberhardtWEEPetersS Phase II single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). [abstract] Eur J Cancer 2015 51 3 abstr 16LBA S71718 10.1016/S0959-8049(16)31938-4Open DOISearch in Google Scholar

7Reck M, Rodriguez-Abreu D, Robinson AG, Hui RN, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. New Engl J Med 2016; 375: 1823-33. 10.1056/Nejmoa1606774ReckM Rodriguez-AbreuDRobinsonAGHuiRNCsosziTFulopA Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer New Engl J Med 2016 375 1823 33 10.1056/Nejmoa1606774Open DOISearch in Google Scholar

8Socinski M, Creelan B, Horn L, Reck M, Paz-Ares L, Steins M, et al. CheckMate 026: A phase 3 trial of nivolumab vs investigator’s choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage IV/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC. [abstract]. Ann Oncol 2016; 27(Suppl): abstr LBA7. 10.1093/annonc/ mdw435.39SocinskiMCreelanBHornLReckM Paz-AresLSteinsM CheckMate 026: A phase 3 trial of nivolumab vs investigator’s choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage IV/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC. [abstract] Ann Oncol 2016 27 LBA7 10.1093/annonc/ mdw435.39Open DOISearch in Google Scholar

9Kumar R, Collins D, Dolly S, McDonald F, O’Brien ME, Yap TA. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer. Curr Probl Cancer 2017; 41: 111-24. 10.1016/j.currproblcancer.2016.12.002KumarRCollinsDDollySMcDonaldFO’BrienMEYapTA. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer Curr Probl Cancer 2017 41 111 24 10.1016/j.currproblcancer.2016.12.002Open DOISearch in Google Scholar

10Califano R, Kerr K, Morgan RD, Lo Russo G, Garassino M, Morgillo F, et al. Immune checkpoint blockade: a new era for non-small cell lung cancer. Curr Oncol Rep 2016; 18: 59. 10.1007/s11912-016-0544-7CalifanoRKerrKMorganRD Lo RussoGGarassinoMMorgilloF Immune checkpoint blockade: a new era for non-small cell lung cancer Curr Oncol Rep 2016 18 59 10.1007/s11912-016-0544-7Open DOISearch in Google Scholar

11Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba, II, Hirsch FR. Programmed death-ligand 1 immunohistochemistry in lung cancer: In what state is this art? J Thorac Oncol 2015; 10: 985-9. 10.1097/JTO.0000000000000526KerrKMTsaoMSNicholsonAGYatabeYWistubaIIHirschFR. Programmed death-ligand 1 immunohistochemistry in lung cancer: In what state is this art? J Thorac Oncol 2015 10 985 9 10.1097/JTO.0000000000000526Open DOISearch in Google Scholar

12Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-7. 10.1038/nature14011HerbstRSSoriaJCKowanetzMFineGDHamidOGordonMS Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 2014 515 563 7 10.1038/nature14011Open DOISearch in Google Scholar

13Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thoracic Oncol 2017; 12: 208-22. 10.1016/j.jtho.2016.11.2228HirschFRMcElhinnyAStanforthD Ranger-MooreJJanssonMKulangaraK PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project J Thoracic Oncol 2017 12 208 22 10.1016/j.jtho.2016.11.2228Open DOISearch in Google Scholar

14Scheel AH, Dietel M, Heukamp LC, Johrens K, Kirchner T, Reu S, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Modern Pathol 2016; 29: 1165-72. 10.1038/ modpathol.2016.117ScheelAHDietelMHeukampLCJohrensKKirchnerTReuS Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas Modern Pathol 2016 29 1165 72 10.1038/ modpathol.2016.117Open DOISearch in Google Scholar

15McLaughlin J, Han G, Schalper K, Carvajal-Hausdorf D, Pelekanou V, Rehman J et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. Jama Oncol 2016; 2: 46-54. 10.1001/jamaoncol.2015.3638McLaughlinJHanGSchalperK Carvajal-HausdorfDPelekanouV RehmanJ Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer Jama Oncol 2016 2 46 54 10.1001/jamaoncol.2015.3638Open DOISearch in Google Scholar

16Ratcliffe MJ, Sharpe A, Midha A, Barker C, Scorer P, Walker J. A comparative study of PD-L1 diagnostic assays and the classification of patients as PD-L1 positive and PD-L1 negative. [abstract]. Cancer Res 2016; 76(Suppl): abstr LB-094. 10.1158/1538-7445.AM2016-LB-094RatcliffeMJSharpeAMidhaABarkerCScorerPWalkerJ. A comparative study of PD-L1 diagnostic assays and the classification of patients as PD-L1 positive and PD-L1 negative. [abstract] Cancer Res 2016 76(Suppl) abstr LB-094 10.1158/1538-7445.AM2016-LB-094Open DOISearch in Google Scholar

17Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124-8. 10.1126/science.aaa1348RizviNAHellmannMDSnyderAKvistborgPMakarovVHavelJJ Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer Science 2015 348 124 8 10.1126/science.aaa1348Open DOISearch in Google Scholar

18Hellmann M, Rizvi N, Wolchok JD, Chan TA. Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. Mol Cell Oncol 2016; 3: e1048929. 10.1080/23723556.2015.1048929HellmannMRizviNWolchokJDChanTA. Genomic profile smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma Mol Cell Oncol 2016 3 e1048929 10.1080/23723556.2015.1048929Open DOISearch in Google Scholar

19Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 2016; 27: 147-53. 10.1093/annonc/mdv489IlieM Long-MiraEBenceCButoriCLassalleSBouhlelL Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies Ann Oncol 2016 27 147 53 10.1093/annonc/mdv489Open DOISearch in Google Scholar

20Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014; 50: 1361-9. 10.1016/j.ejca.2014.01.018YangCYLinMWChangYLWuCTYangPC. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes Eur J Cancer 2014 50 1361 9 10.1016/j.ejca.2014.01.018Open DOISearch in Google Scholar

21Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. Eur J Cancer 2016; 57: 91-103. 10.1016/j.ejca.2015.12.033YangCYLinMWChangYLWuCTYangPC. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma Eur J Cancer 2016 57 91 103 10.1016/j.ejca.2015.12.033Open DOISearch in Google Scholar

22D′Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 2015; 112: 95-102. 10.1038/bjc.2014.555D’InceccoAAndreozziMLudoviniV RossiE CapodannoALandiL PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients Br J Cancer 2015 112 95 102 10.1038/bjc.2014.555Open DOISearch in Google Scholar

23Schmidt LH, Kummel A, Gorlich D, Mohr M, Brockling S, Mikesch JH, et al. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS One 2015; 10: e0136023. 10.1371/journal. pone.0136023SchmidtLHKummelAGorlichDMohrMBrocklingSMikeschJH PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups PLoS One 2015 10 e0136023 10.1371/journal. pone.0136023Open DOISearch in Google Scholar